Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
China
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan